Cliff Asness's RARE Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 1.36 M shares of Ultragenyx Pharmaceutical Inc. (RARE) worth $31.29 M, representing 0.02% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 32 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in RARE, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 947,273 shares. Largest reduction occurred in Q4 2024, reducing 763,826 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Ultragenyx Pharmaceutical (RARE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ultragenyx Pharmaceutical (RARE) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +614,315 | Add 82.33% | 1.36 M | $23.00 |
| Q3 2025 | +493,849 | Add 195.71% | 746,182 | $30.08 |
| Q2 2025 | +160,286 | Add 174.13% | 252,333 | $36.36 |
| Q1 2025 | -188,500 | Reduce 67.19% | 92,047 | $35.93 |
| Q4 2024 | -763,826 | Reduce 73.14% | 280,547 | $42.07 |
| Q3 2024 | +947,273 | Add 975.56% | 1.04 M | $55.35 |
| Q2 2024 | -154,097 | Reduce 61.35% | 97,100 | $41.10 |
| Q1 2024 | +80,508 | Add 47.17% | 251,197 | $46.46 |
| Q4 2023 | +170,689 | New Buy | 170,689 | $47.82 |
| Q2 2023 | -35,911 | Sold Out | 0 | $0.00 |
| Q1 2023 | +19,997 | Add 125.66% | 35,911 | $39.13 |
| Q4 2022 | +5,692 | Add 55.68% | 15,914 | $45.79 |
| Q3 2022 | +10,222 | New Buy | 10,222 | $41.38 |
| Q3 2021 | -9,500 | Sold Out | 0 | $0.00 |
| Q2 2021 | -19,284 | Reduce 67.00% | 9,500 | $95.37 |
| Q1 2021 | -9,234 | Reduce 24.29% | 28,784 | $113.85 |
| Q4 2020 | +8,959 | Add 30.83% | 38,018 | $138.43 |
| Q3 2020 | +1,576 | Add 5.73% | 29,059 | $82.18 |
| Q2 2020 | +3,836 | Add 16.22% | 27,483 | $78.23 |
| Q1 2020 | +18,220 | Add 335.73% | 23,647 | $44.45 |
| Q4 2019 | +5,427 | New Buy | 5,427 | $42.75 |
| Q3 2019 | -7,283 | Sold Out | 0 | $0.00 |
| Q2 2019 | +7,283 | New Buy | 7,283 | $63.44 |
| Q1 2019 | -7,858 | Sold Out | 0 | $0.00 |
| Q4 2018 | +976 | Add 14.18% | 7,858 | $43.52 |
| Q3 2018 | +6,882 | New Buy | 6,882 | $76.29 |
| Q3 2016 | -6,419 | Sold Out | 0 | $0.00 |
| Q2 2016 | -11,924 | Reduce 65.01% | 6,419 | $48.92 |
| Q1 2016 | -14,750 | Reduce 44.57% | 18,343 | $63.29 |
| Q4 2015 | -1,684 | Reduce 4.84% | 33,093 | $112.17 |
| Q3 2015 | +12,185 | Add 53.94% | 34,777 | $96.30 |
| Q2 2015 | +22,592 | New Buy | 22,592 | $102.43 |
Cliff Asness's Ultragenyx Pharmaceutical Investment FAQs
Cliff Asness first purchased Ultragenyx Pharmaceutical Inc. (RARE) in Q2 2015, acquiring 22,592 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Ultragenyx Pharmaceutical Inc. (RARE) for 32 quarters since Q2 2015.
Cliff Asness's largest addition to Ultragenyx Pharmaceutical Inc. (RARE) was in Q3 2024, adding 1,044,373 shares worth $57.81 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 1,360,497 shares of Ultragenyx Pharmaceutical Inc. (RARE), valued at approximately $31.29 M.
As of the Q4 2025 filing, Ultragenyx Pharmaceutical Inc. (RARE) represents approximately 0.02% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Ultragenyx Pharmaceutical Inc. (RARE) was 1,360,497 shares, as reported at the end of Q4 2025.